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Introduction
The tunichromes are small, modified peptides isolated from the blood cells of marine organisms belonging to the Class Ascidiacea.[ref1, ref2, ref3] Structurally, these natural products are typified by the presence of a C-terminal decarboxy- 2,3 -enamide fragment. While the C-terminus amino acid is usually tyrosine, 3,4-dihydroxyphnylalanine (DOPA) or 3,4,5-trihydroxyphenylalanine (TOPA)-derived, the halocyamines (e.g. A, 1) are unusual in that the C-terminus moiety is derived from 6-bromo-tryptophan. A number of ecological roles have been proposed for the tunichromes, varying from tunic formation (cross-linking) [ref4], acting as a primitive wound repair system, to metal ion sequestration [ref5] or that they act as antimicrobial agents.
[ref4] Indeed there is growing body of biochemical evidence that many of these roles are at least feasible.
As part of our ongoing investigation of the chemistry and biology of tunichromes, we have recently reported the synthesis and structural confirmation of the tunichromes and halocyamine A
(1).
[ref7] With only modest levels of antibacterial activity being observed for synthetic halocyamine A, we sought to use our robust synthetic methodology to prepare novel halocyamine A analogues that explored the influence of bromine substitution and of the His and DOPA amino acids on the biological activity. Herein we report the synthesis and antibacterial activities of these halocyamine A analogues.
Fig 1.
Structures of halocyamine A (1) and des-bromo analogue 2
Results and discussion
In our previously reported synthesis of halocyamine A (1), the natural product was disconnected at the DOPA-Gly amide bond to give two fragments, Fmoc-His(Trt)-DOPA(TBS)2-OH (3) and Zenamide 4 (Fig. 2) .
[ref7] The two fragments were prepared separately using Fmoc solid phase peptide synthesis (SPPS) and ruthenium-catalysed hydroamidation of an indole-acetylene, respectively.
Fig 2. Fragments 3 -5.
In the current project, we sought to explore the influence, if any, of bromine substitution and each of the amino acids L-His and L-DOPA on the observed antibacterial activity of halocyamine A. To this end, our first target was des-bromo halocyamine A 2, which required synthesis of indole-enamide 5.
The known indolic alkyne 6 [Ref8 Unsworth] was subjected to hydroamidation with Fmocglycinamide using 5 mol% bis(2-methylallyl) (1,5-cyctooctadiene) ruthenium(II) heated at 70 °C for 32 h to give glycyl-Z-enamide 7 (69%) and by-product (E)-enyne 8[ref7] (18%) (Scheme 1). Enamide 7 was then deprotected (TFA/CH2Cl2) to give 5 in 89% yield.
Scheme 1. Reagents and conditions:
(i) Fmoc-glycinamide (0.5 eq.), bis(2-methylallyl) (1,5- cycloocta-diene)ruthenium(II) (0.025 eq.), 1,4-bis(dicyclohexylphosphino)butane (0.03 eq.), ytterium triflate (0.02 eq.), DMF, H2O, 70 °C, 32 h, 69% (7) and 18% (8); (ii) TFA (60 eq.), CH2Cl2, 0 °C, 8 h, 89%.
EDC-mediated coupling of enamide 5 and protected dipeptide Fmoc-His(Trt)-DOPA(TBDMS)2-OH 3 [ref7] afforded the protected halocyamine analogue 9 in 39% yield (Scheme 2).
Step-wise fmoc deprotection (piperidine, DMF, 20 min) to give 10 (68% yield), followed by desilylation (triethylamine trihydrofluoride, THF, 55 min) to give 11 (69% yield) and lastly, removal of the trityl group (HCl/HFIP, H2O, TIS, 1 h) afforded des-bromo halocyamine A 2 as the dihydrochloride salt in 73% yield.
Scheme 2. Reagents and conditions:
(i) EDC.HCl (1.5 eq.), HOBt (2 eq.), DIPEA (6 eq.), CH2Cl2, 9
h, 39%; (ii) piperidine, DMF, r.t. 20 min, 68%; (iii) Et3N.3HF, THF, 0 °C, 55 min, 69%; (iv) 0.01 N HCl/HFIP, H2O, TIS, r.t., 1 h, 73%.
We next explored the antibacterial influence of the L-histidine and/or L-DOPA residues of halocyamine A by preparing two L-alanine-substituted variants 12 and 13. The first of these analogues (12), where Ala replaced His, required the protected dipeptide Fmoc-Ala-DOPA(TBDMS)2-OH (14) which was prepared using standard Fmoc-SPPS methodology in 85%
yield (see experimental). Bromo-indole enamide 4[ref7] was then coupled (EDC, HOBt, DIPEA, 7.5 h) with 14 to give 15 in 42% yield (Scheme 3). Removal of the Fmoc protecting group (piperidine, DMF, 20 min) gave the chromatographically-separable (Z)-16 (36%) and (E)-16 (31% ] analogue was the enhanced activity towards the Gram-negative bacterium E. coli (MIC 8 25-50 M) for the fmoc/trityl (19) and trityl-protected (19) intermediates. Although these same two compounds also exhibited cytotoxicity towards the L6 cell line (IC50 65.6 and 25.6 M, respectively) the observation of antibacterial activity for these compounds and not for the corresponding detritylated analogue (13) suggests that the presence of a sterically bulky lipophilic residue at the Hisresidue position in halocyamine A may be a useful starting point for the discovery of novel Gramnegative antibacterials.
Gram-positive antibacterial activity was observed for both di-alaninyl analogues with the di-Lalaninyl variant 20 exhibiting activity towards S. aureus (MIC 12.5 M) and the di-D-alaninyl analogue 21 exhibiting activity towards both S. aureus and E. faecalis (both MIC 50 M). Modest cytotoxicity was observed for these analogues (IC50 115.8 and 142 M, respectively), equating to a selectivity index (= cytotoxicity IC50 / antibacterial MIC) in the case of di-L-alaninyl 20 of close to ten. The antibacterial activity for both di-alaninyl analogues was dependent upon a free amine at the N-terminus, as both fmoc-protected precursors (24 and 25) were inactive. tert-butyl 3,3'-(but-1-en-3-yne-1,4-diyl) 
(E)-bis(1H-indole-1-carboxylate) (8 HF8-14)
Fmoc-Gly-NH2 (0.296 g, 1.00 mmol), tert-butyl 3-ethynyl-1H-indole-carboxylate (0.482 g, 2.00 mmol), bis(2-methylallyl) (1,5-cycloocta-diene) as a brown oil while elution with a more polar solvent mixture (n-hexane/EtOAc 1:1 to EtOAc) gave 7 HF4-68 (0.220 g, 69%) as a yellow oil. Hz, H-6), 3.47 (2H, s, H2-2), 1.68 (9H, s, CO2C(CH3)3); 13 
(Z)-N-(2-(1H-Indol-3-yl)vinyl)-2-aminoacetamide (5 HF4-154)
A solution of 7 HF4-68 (0.17 g, 0.436 mmol) in CH2Cl2 (2 mL) was stirred at 0 ºC under N2
for 5 min before TFA (2 mL, 26.1 mmol) was added dropwise. The solution was then stirred for a further 8 h at 0 ºC. The reaction was quenched with sat. aq. NaHCO3 (20 mL) and extracted with EtOAc (4 x 20 mL). The organic layers were combined and dried in vacuo. The crude black oil was purified by silica gel column chromatography (eluting with EtOAc to CH2Cl2/MeOH 9:1) to afford 5 HF4-154 (0.13 g, 89%) as a black oil. Rƒ 0.50 (CH2Cl2/ 
(9H-Fluoren-9-yl)methyl ((S)-1-(((S)-1-((2-(((Z)-2-(1H-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)-1-oxopropan-2-yl)amino)-1-oxo-3-(1-trityl-1H-imidazol-4-yl)propan-2-yl)carbamate (10 HF7-118)
To a 
for C73H82N7O7Si2, 1224.5809).
(S)-N-(2-(((Z)-2-(1H-Indol-3-yl)vinyl)amino)-2-oxoethyl)-2-((S)-2-amino-3-(1-trityl-1H-imidazol-4-yl)propanamido)-3-(3,4-bis((tert-butyldimethylsilyl) oxy)phenyl)propanamide (10 HF7-

88)
Piperidine (0.18 mL, 1:4 v/v in DMF) was added to 9 HF7-118 (43.9 mg, 35.9 µmol) and stirred at r.t. under N2 for 20 min. Water (10 mL) was added to the solution and the aqueous layer was extracted with EtOAc (4 x 20 mL). The organic layers were combined and dried in vacuo. The crude product was purified by silica gel column chromatography (eluting with EtOAc to CH2Cl2/ 
(S)-N-(2-(((Z)-2-(1H-Indol-3-yl)vinyl)amino)-2-oxoethyl)-2-((S)-2-amino-3-(1-trityl-1H-imidazol-4-yl)propanamido)-3-(3,4-dihydroxy phenyl)propanamide (11 HF8-25)
Triethylamine trihydrofluoride (4.59 µL, 28.5 µmol) was added to a solution of 10 HF7-88 (9.5 mg, 9.5 µmol) in THF (0.50 mL) at 0 ºC and stirred under N2 for 55 min. The reaction mixture was dried under a stream of N2 and water (15 mL) was added. The aqueous layer was extracted with CH2Cl2 (4 x 20 mL) and the organic layers were combined and solvent was removed in vacuo to give a yellow oil. 
Des-bromo halocyamine A dihydrochloride (2 HF7-137)
A cocktail solution of 0.01 N HCl/HFIP-TIS/H2O (2 mL, 95:2.5:2.5) was added to 11 HF8-25 (48.6 mg, 0.0628 mmol) and stirred for 1 h. The reaction was dried under a stream of N2.
Purification by C8 column chromatography (eluting with H2O to H2O/MeOH 6:4) afforded 
(9H-Fluoren-9-yl)methyl ((S)-1-(((S)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)-1-((2-(((Z)-2-(6-bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl) amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl) carbamate (15 HF7-81)
To a solution of enamide 4 HF3.1 (0.14 g, 0.49 mmol), 14 HF7-60 (0.36 g, 0.49 mmol), EDC.HCl (0.14 g, 0.73 mmol) and HOBt (0.13 g, 0.98 mmol) in CH2Cl2 (5 mL) under N2, was added DIPEA (0.51 mL, 2.9 mmol) and the solution was stirred at r.t. for 7.5 h. Water (10 mL) was added and the crude reaction product was extracted with EtOAc (4 x 15 mL). The organic layers were combined, dried (MgSO4), filtered and solvent removed in vacuo to give a crude oil. Purification by silica gel column chromatography (eluting with n-hexane/EtOAc 9:1 to n-hexane/ 
(S)-2-((S)-2-Aminopropanamido)-3-(3,4-bis((tert-butyldimethylsilyl)oxy)phenyl)-N-(2-((2-(6-bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl)propanamide (16 HF7-140)
Piperidine (0.23 mL, 20% in DMF) was added to 15 HF7-81 (47.0 mg, 0.0473 mmol) and the solution was stirred under N2 at r.t. for 20 min. EtOAc (15 mL) was added and the mixture was washed with water (5 mL). The aqueous layer was further washed with EtOAc (3 x 15 mL) and then the organic layers were combined and dried in vacuo. The crude product was purified by silica gel column chromatography (eluting with EtOAc to CH2Cl2/MeOH 9:1), to afford Z-16 HF7-140Z (13.0 mg, 36%) and E-16 HF7-140E (13.0 mg, 31%) as yellow oils. 
E-16
(S)-1-(((S)-1-((2-(((Z)-2-(6-Bromo-1H-indol-3-yl)vinyl)amino)-2-oxoethyl)amino)-3-(3,4-dihydroxy phenyl)-1-oxopropan-2-yl)amino)-1-oxopropan-2-aminium 2,2,2-trifluoroacetate (12
HF7-154)
A solution of Z-16 HF7-140Z (18.2 mg, 0.0236 mmol) in THF (2 mL 
Fmoc-His(Trt)-Ala-OH (17 HF8-62)
A solution of Fmoc-L-Ala-OH (0.93 g, 3.0 mmol) in CH2Cl2 (25 mL) and DMF (2 mL) was added to 2-chlorotrityl chloride resin (6 g, loading at 0.5 mmol/g), followed by DIPEA (0.52 mL, 3.0 mmol). After the resin mixture was agitated for 10 min, DIPEA (0.78 mL, 4.5 mmol) was added and the mixture was further shaken for 2 h. The solution was drained off and the resin was washed with DMF (30 mL). A solution of CH2Cl2/MeOH/DIPEA (20 mL, 80:15:5) was added to the mixture and shaken for 30 min. The solution was drained and the procedure was repeated. The resin was then washed with DMF (20 mL). Piperidine in DMF (15 mL, 1:4) was added to the resin mixture and shaken for 5 min. The liquid was drained off and piperidine washing was repeated for another 20 min.
The amino acid-loaded resin was thoroughly washed with DMF (30 mL), isopropanol (30 mL) and n-hexane (30 mL). The resin was then dried under vacuum overnight. CH2Cl2 (40 mL) was added to the resin and left for 30 min. The solution was drained and a solution of HBTU (4.27 g, 11.25 mmol), HOBt (1.72 g, 11.25 mmol), Fmoc-His(Trt)-OH (4.65 g, 7.5 mmol) and DIPEA (2.61 mL, 15.0 mmol) in DMF (11.3 mL) was added to the resin. The amino acid resin mixture was agitated for 5 h. The solution was then drained and washed with DMF (30 mL), isopropanol (30 mL) and n-hexane ( 3303, 2160, 1653, 1494, 1448, 1230, 1041, 1002 2 Hz, 7.47 (1H, s, m, 7.34 (1H, s, m, m, m, m, m, 6.61 (1H, s, 6.08 (1H, d, J = 6.3 Hz, 5.80 (1H, d, J = 9.2 Hz, m, m, 4.15 (1H, t, J = 6.3 Hz, CO2CH2CH), 4.04 (1H, dd, J = 16.5, 6.1 Hz, 3.87 (1 H, dd, J = 16.5, 5.6 Hz, 8 Hz, m, 4.05 (1H, dd, J = 16.9, 5.8 Hz, 3.93 (1H, dd, J = 16.9, 5.6 Hz, 3.66 (1H, s, 2.94 (1H, dd, J = 14.6, 4.8 Hz, 2.84 (1H, dd, J = 14.6, 5.5 Hz, 1.32 (3H, d, J = 7.2 Hz, Subsequent purification by C8 column chromatography (eluting with H2O to H2O/MeOH 25:75) afforded 13 HF8-141 as an inseparable 1Z:0.9E mixture (yellow oil) (39.9 mg, 83%).
The mixture had the following properties: Rƒ 0.59 (butan-1-ol/acetic acid/H2O 2 
Fmoc-L-Ala-L-Ala-OH (22 HF8-58)
A solution of Fmoc-Ala-OH (0.93 g, 3.0 mmol) in CH2Cl2 (25 mL) was added to 2-chlorotrityl chloride resin (6 g, loading at 0.5 mmol/g), followed by DIPEA (0.52 mL, 3.0 mmol). After the resin mixture was agitated for 14 min, DIPEA (0.78 mL, 4.5 mmol) was added and the mixture was further shaken for 2.5 h. The solution was drained off and the resin was washed with DMF (20 mL). A solution of CH2Cl2/MeOH/DIPEA (40 mL, 80:15:5) was added to the mixture and shaken for 30 min.
The solution was drained and the procedure was repeated. The resin was then washed with DMF (20 mL). Piperidine in DMF (15.0 mL, 1:4) was added to the resin mixture and shaken for 10 min. The liquid was drained off and piperidine washing was repeated for another 40 min. The amino acidloaded resin was thoroughly washed with DMF (35 mL), isopropanol (35 mL) and n-hexane (35 mL).
The resin was then dried under vacuum for 30 min and placed in a desiccator overnight. CH2Cl2 (50 mL) was added to the resin and left for 1 h. The solution was drained and a solution of HBTU (4.27 g, 11.25 mmol), HOBt (1.72 g, 11.25 mmol), Fmoc-Ala-OH (2.34 g, 7.5 mmol) and DIPEA (2.61 mL, 15.0 mmol) in DMF (11.3 mL) was added. The amino acid resin mixture was agitated for 4 h. 
Antibacterial assays[ref10]
The antibacterial activity of the compounds was studied by determination of minimum inhibitory concentrations (MICs) using the standard broth dilution method in accordance with the NCCLS guidelines M7-A2. Briefly, the MICs were determined with an inoculum of 10 
In vitro cytotoxicity assay[ref11]
Assays were performed in 96-well microtiter plates, each well containing 100 μL of RPMI 1640 medium supplemented with 1% L-glutamine (200 mM) and 10% fetal bovine serum, and 4 × 10 4 L6 cells (a primary cell line derived from rat skeletal myoblasts). Serial drug dilutions of seven 3-fold dilution steps covering a range from 90 to 0.123 μg/mL were prepared. After 72 h of incubation, the plates were inspected under an inverted microscope to assure growth of the controls and sterile conditions. Alamar Blue solution (10 μL) was then added to each well and the plates incubated for another 2 h. Then the plates were read with a Spectramax Gemini XS microplate fluorometer using an excitation wavelength of 536 nm and an emission wavelength of 588 nm. Data were analysed using the microplate reader software Softmax Pro. Podophyllotoxin was the reference drug used.
